ICER says ‘marginal’ benefits for AbbVie’s new RA drug

AbbVie’s Rinvoq rheumatoid arthritis drug is an important part of the company’s strategy to replace lost sales as its mega-blockbuster Humira finally succumbs to cheaper biosimilar competitors over the coming years.